Results 21 to 30 of about 19,651 (218)

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

Cardiologia Hungarica, 2023
Eszter Dalma Palinkaš, Robert Sepp
exaly   +2 more sources

Cardiac myosin inhibitors - a cutting-edge solution for the management of hypertrophic cardiomyopathy: a narrative review. [PDF]

Ann Med Surg (Lond)
Younas A, Qadri M, Ijlal A, Khan T, Pirzada L, Kumari V, Mubbashir A, Singh PK, Sherwani MRK, Noor R, Nausheen F, Ahmad B, Rahim H, Akilimali A.   +13 more
europepmc   +2 more sources

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive). [PDF]

Eur Heart J Suppl
Biagini E, Schiavo MA.
europepmc   +2 more sources

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies

Frontiers in Physiology, 2022
Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana, Masataka Kawana, James A. Spudich, Kathleen M. Ruppel   +3 more
doaj   +1 more source

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +1 more source

Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten

Therapeutic Advances in Chronic Disease, 2022
Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterised by unexplained left ventricular hypertrophy. Left ventricular outflow tract obstruction is an integral component of the disease, often resulting in significant symptoms, but ...
Susan Mathai, Lynne Williams
doaj   +1 more source

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +1 more source

Disruption of calcium homeostasis in cardiomyocytes underlies cardiac structural and functional changes in severe sepsis. [PDF]

PLoS ONE, 2013
Sepsis, a major cause of morbidity/mortality in intensive care units worldwide, is commonly associated with cardiac dysfunction, which worsens the prognosis dramatically for patients.
Mara R N Celes, Lygia M Malvestio, Sylvia O Suadicani, Cibele M Prado, Maria J Figueiredo, Erica C Campos, Ana C S Freitas, David C Spray, Herbert B Tanowitz, João S da Silva, Marcos A Rossi   +10 more
doaj   +1 more source

Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction

Life, 2023
Despite the improvements in the treatment of coronary artery disease (CAD) and acute myocardial infarction (MI) over the past 20 years, ischemic heart disease (IHD) continues to be the most common cause of heart failure (HF). In clinical trials, over 70%
Sabina Andreea Leancă, Irina Afrăsânie, Daniela Crișu, Iulian Theodor Matei, Ștefania Teodora Duca, Alexandru Dan Costache, Viviana Onofrei, Ionuţ Tudorancea, Ovidiu Mitu, Minerva Codruța Bădescu, Lăcrămioara Ionela Șerban, Irina Iuliana Costache   +11 more
doaj   +1 more source

Differentiation of spontaneously contracting cardiomyocytes from non-virally reprogrammed human amniotic fluid stem cells. [PDF]

PLoS ONE, 2017
Congenital heart defects are the most common birth defect. The limiting factor in tissue engineering repair strategies is an autologous source of functional cardiomyocytes.
Aaron J Velasquez-Mao, Christopher J M Tsao, Madeline N Monroe, Xavier Legras, Beatrice Bissig-Choisat, Karl-Dimiter Bissig, Rodrigo Ruano, Jeffrey G Jacot   +7 more
doaj   +1 more source